IlluminaXSWX:ILMN -0.79%76 OCF Yield % is 4.20 as of Jun. 27, 2026, which is 71% above its 10-year median of 2.45. GuruFocus rates XSWX:ILMN with a GF Score™ of 76/100 and a GF Value™ of CHF105.51. The stock has 7 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Illumina ranks better than 64.65% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
The historical rank and industry rank for Illumina's OCF Yield % or its related term are showing as below:
XSWX:ILMN'
s OCF Yield % Range Over the Past 10 Years
Min: 0.64 Med: 2.45 Max: 8.83
Current: 4.2
During the past 13 years, the highest OCF Yield % of Illumina was 8.83%. The lowest was 0.64%. And the median was 2.45%.
XSWX:ILMN's OCF Yield % is ranked better than 64.65% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.05
vs XSWX:ILMN: 4.20
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Illumina OCF Yield % Related Terms
Illumina OCF Yield % Historical Data
* Premium members only.
The historical data trend for Illumina's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Illumina's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Illumina OCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Illumina's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Illumina (XSWX:ILMN) has a OCF Yield % of 4.20 as of Jun. 27, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Illumina and its competitors. This is 71% above median its historical median of 2.45. Over the past decade, Illumina's OCF Yield % has ranged from 0.64 to 8.83. According to the industry distribution chart, Illumina ranks #76 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 35.3%.
Is Illumina's OCF Yield % too high?
Illumina's current OCF Yield % of 4.20 is 71% above median its 10-year median of 2.45. Over the past 10 years, this metric has ranged from a low of 0.64 to a high of 8.83. The Medical Diagnostics & Research industry median OCF Yield % is 1.05. Illumina's value of 4.20 is 300% above this industry median. Based on the distribution chart, Illumina ranks #76 out of 215 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Illumina has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Illumina's OCF Yield % compare to MTD and DGX?
According to the Medical Diagnostics & Research industry distribution chart, Illumina ranks #76 out of 215 companies for OCF Yield %. This puts Illumina in the upper half of its industry. The industry median OCF Yield % is 1.05. Illumina's value of 4.20 is 300% above this benchmark. Historically, Illumina's own OCF Yield % has ranged from 0.64 to 8.83 over the past decade. While the company's 10-year median is 2.45 vs. the industry median of 1.05, Illumina has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Medical Diagnostics & Research company?
The median OCF Yield % among Medical Diagnostics & Research companies is 1.05, based on 215 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Illumina's current OCF Yield % of 4.20 is 300% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Illumina and its competitors. For the Medical Diagnostics & Research industry, the median OCF Yield % is 1.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Illumina's current OCF Yield % is 4.20, which is 71% above median its own 10-year median of 2.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Illumina stock overvalued right now?
Illumina (XSWX:ILMN) has a current OCF Yield % of 4.20. The stock's GF Value™ is CHF105.51, compared to a current price of CHF143.95 — trading 36.4% above its estimated fair value. The current OCF Yield % is 4.20, which is 71% above median its 10-year median of 2.45 and 300% above the Medical Diagnostics & Research industry median of 1.05. Illumina's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Illumina (XSWX:ILMN), the current OCF Yield % is 4.20 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Illumina (XSWX:ILMN) Overvalued in 2026?
Based on GuruFocus' analysis, Illumina stock appears to be overvalued.
The current stock price of CHF143.95 is trading 36.4% above its estimated GF Value™ of CHF105.51.
Key valuation signals for XSWX:ILMN:
OCF Yield %: 4.20 (71% above median its 10-year median of 2.45)
GF Value™: CHF105.51 vs. price of CHF143.95 (36.4% above fair value)
Industry Position: 300% above the Medical Diagnostics & Research median (#76 of 215)
No single metric tells the full story. See the XSWX:ILMN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
76GF Score
Get the complete analysis for XSWX:ILMN
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ILMN has been successfully added to your 
